Competition to be seen intensifying in hepatitis B drugs
Published: 2010-05-06 06:57:00
Updated: 2010-05-06 06:57:00
Multination pharmaceutical companies, such as GlaxoSmithKline (GSK), BMS and Novartis, are stepping up their maketing in domestic hepatitis B treatment drug market valued at 100 billion won, which is forecast to become more competitive ever this year.
Meanwhile, a total of 34 local drug makers...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
